PertuzumabPertuzumabPertuzumabPertuzumabPertuzumab%E3%83%9A%E3%83%AB%E3%83%84%E3%82%BA%E3%83%9E%E3%83%96%D0%9F%D0%B5%D1%80%D1%82%D1%83%D0%B7%D1%83%D0%BC%D0%B0%D0%B1PertuzumabPertuzumabe%D0%9F%D0%B5%D1%80%D1%82%D1%83%D0%B7%D1%83%D0%BC%D0%B0%D0%B1PertuzumabPertuzumab%D0%9F%D0%B5%D1%80%D1%82%D1%83%D0%B7%D1%83%D0%BC%D0%B0%D0%B1Q1998021%E5%B8%95%E5%A6%A5%E7%8F%A0%E5%8D%95%E6%8A%97
about
P3354
P3781
A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast CancerThe Use of FES-PET Imaging as a Tool to Detect a Possible Reversion of Estrogen Receptor (ER)-α Status in Patients With Metastatic Breast Cancer HER2 + and ERα Neg Treated With Trastuzumab + Pertuzumab + Taxane.Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric CancerMINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.The Efficacy of Acupuncture in Treating Chemotherapy Side Effects in Breast Cancer PatientsNeoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2To Reduce the Use of Chemotherapy in Elderly Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)Neoadjuvant Her2-targeted Therapy and Immunotherapy With PembrolizumabTrial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BCRandomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast CancerA Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast CancerA Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast CancerA Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast CancerA Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast CancerNeoadjuvant Dose-Dense For Early Her2Neu Positive Breast CancerA Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast CancerOmission of Radiation in Patients With Her-2 Positive Breast CancerPaclitaxel, Trastuzumab, and Pertuzumab With or Without Atezolizumab in Treating Patients With Metastatic Breast CancerA Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast CancerAnastrozole, Palbociclib, Trastuzumab and Pertuzumab in Her-positive, Her2-positive Metastatic BreastA Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical TrialImproving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast CancerTAHP for Patients With HER2-positive Early Breast Cancer and Subsequent AHP Adjuvant tHerapy After SurgeryA Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast CancerTargeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid TumorsA Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Trastuzumab, Pertuzumab in Combination With Trastuzumab, or Ado-Trastuzumab EmtansineA Personalized Medicine Study for Patients With Advanced Cancer of the Breast, Prostate, Pancreas or Those With Refractory Acute Myelogenous LeukemiaCopper (Cu) 64-DOTA-Trastuzumab PET Imaging in Predicting Response to Treatment With Trastuzumab and Pertuzumab Before Surgery in Patients With HER2 Positive Breast CancerObservational Study of Pertuzumab Safety in Participants With Breast CancerCombination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine CancersA Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic AdenocarcinomaI-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerA Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary SiteTrastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to TrastuzumabDocetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
P4844
Role of pertuzumab in the treatment of HER2-positive breast cancerPertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancerTumor lysis syndrome following trastuzumab and pertuzumab for metastatic breast cancer: a case report.Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese patients with solid tumors.Pertuzumab Increases 17-AAG-Induced Degradation of ErbB2, and This Effect Is Further Increased by Combining Pertuzumab with TrastuzumabMulti-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patientsPertuzumab for the treatment of patients with previously untreated HER2-positive metastatic breast cancerWeekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study.Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancerPharmacokinetic and exposure-response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer.HER-dimerization inhibitors: evaluating pertuzumab in women's cancers.HER2-Positive Metastatic Breast Cancer Patients Receiving Pertuzumab in a Community Oncology Practice Setting: Treatment Patterns and OutcomesPrecision medicine and personalized breast cancer: combination pertuzumab therapy.Pertuzumab for the treatment of ovarian cancer.CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer.Pertuzumab and trastuzumab: the rationale way to synergy.Pertuzumab Plus Chemotherapy for Platinum-Resistant Ovarian Cancer: Safety Run-in Results of the PENELOPE Trial.Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts.Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study.Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer RegistryPharmacokinetic and exploratory exposure-response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY studyTargeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancerPrimary Mediastinal HER2-positive Apocrine Carcinoma in Mature Teratoma Treated With Anti-HER2 Therapy and ChemoradiationThe Effects of Pertuzumab and Its Combination with Trastuzumab on HER2 Homodimerization and PhosphorylationEORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junctionNeoadjuvant treatment of HER2-positive breast cancer: should therapy differ based on hormone receptor status?
P921
Q61894354-7C9955C2-9647-49F3-B571-FD8C7BAB3A10Q61902815-84450D9A-9A07-47D0-812A-AFD8DFDC27CAQ61909207-9256590B-40FF-4048-B77F-63BB0832D908Q61957306-92789FB7-AE2A-45F2-919A-7579680A4E97Q61957581-EB8771FE-59B3-40BF-93F0-D5F89BCD8159Q61969278-12A15BC1-DE6D-44B6-A1BC-8709D0BD7AE6Q61969608-6F23A5BE-16F2-4C6B-9BAE-8FCDE806DD26Q61969619-029A63B7-4B4D-4FED-8CE5-8227BD9566C5Q62025926-89937B28-4959-46CE-862B-346319A46C56Q62034358-BE219057-480A-4DB4-8EE5-A2715CDF53FCQ62034709-8CF71195-EE31-4689-81B1-014BAD706574Q62040820-08773795-F70E-4249-B1D2-EDF7C8E6209EQ63010732-12333D35-D254-47DC-BB2E-B592959F40B2Q63315749-656CEBD9-2EED-4473-BA87-46A8F605476FQ63316424-A2F6CBBE-454E-4C67-8F65-388F36841345Q63320432-D55B76C9-B4DC-4617-B387-DE5AA83191B3Q63335890-BA3D6EDA-D753-4CBA-B1F0-800B331FE1C6Q63533989-11A400B4-5A14-4D90-94F1-127027C73477Q63571510-031ADA22-AD0E-4B50-A41C-EB89468DCFC9Q63572017-B29DB098-2C41-485D-AAAD-5FF4DCB4614CQ63573128-675DC3E4-5D0C-4648-8EF9-C0DC9FE9B801Q63573361-EF51E035-1A23-407A-AFF1-F59FEB1F9512Q63574691-9FFD39E8-3FBC-4227-8BF6-4E977A2492CAQ63576727-3C5C233E-99A3-4080-9FC6-5D2F6DEE22B9Q63579676-9A27DAFA-27F6-485B-98BC-5B6136634B70Q63582885-1672377C-7ED0-42EB-8E94-3CC62D5B63E6Q63583346-F05B1CEB-B20B-40C8-8FE0-DE6D633E839EQ63590421-2ABEFBAB-FE8C-49D1-9562-4472660A900AQ63590755-B821E747-3465-45CF-A38D-C8467F7B8208Q63591214-4AB2FB11-F587-48C6-82EA-832408059883Q63808351-440C2946-0480-4F24-955B-FA77AFFC215AQ63813272-44B7FF5A-4AFE-4F08-B10C-81548F69468FQ63813450-B1343239-616E-4867-97F4-D60D4FD5FDFDQ63829893-9EB4AF0F-D721-4132-91D8-E77F5B4DE79EQ63830343-49C92A20-F404-4BD2-A19C-AB9884DFEC53Q63833598-F24BA8A5-1B8F-415A-B1B2-22714AC4D994Q64123636-3CC44F58-52FC-402F-84B2-E6A5D0F5ACD2Q64139367-4915D8C9-CCEC-474F-96AD-1EE754D08298Q64149921-81D02C54-C355-44FB-816C-0EC9BFF80805Q64150460-85EB4DAF-AAC1-4496-A92A-2FB30546205F
P4844
description
chemesch Verbindung
@lb
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
component quimic
@oc
name
Pertuzumab
@de
Pertuzumab
@en
Pertuzumab
@es
Pertuzumab
@it
Pertuzumab
@nl
Pertuzumab
@sh
Pertuzumab
@sr
Pertuzumabe
@pt
pertuzumab
@fr
pertuzumab
@pl
type
label
Pertuzumab
@de
Pertuzumab
@en
Pertuzumab
@es
Pertuzumab
@it
Pertuzumab
@nl
Pertuzumab
@sh
Pertuzumab
@sr
Pertuzumabe
@pt
pertuzumab
@fr
pertuzumab
@pl
altLabel
2C4 Antibody
@en
MOAB 2C4
@en
Monoclonal Antibody 2C4
@en
Omnitarg
@en
RG-1273
@en
rhuMAb-2C4
@en
Перьета
@ru
prefLabel
Pertuzumab
@de
Pertuzumab
@en
Pertuzumab
@es
Pertuzumab
@it
Pertuzumab
@nl
Pertuzumab
@sh
Pertuzumab
@sr
Pertuzumabe
@pt
pertuzumab
@fr
pertuzumab
@pl
P31
P486
P592
P6366
P646
P665
P1269
P2115
N0000185031
P2275
Pertuzumab
@en
P231
380610-27-5
P267
P2892
P3345
P3780
P4527
P486
P592
CHEMBL2007641
P6366
2781164504